| 通报号: G/TBT/N/CAN/465 |
ICS号: 11.120
|
发布日期: 2015-08-05
|
截至日期: 2015-10-15
|
通报成员: 加拿大
|
目标和理由: 保护人类安全和健康
|
内容概述: 联合国麻醉药品委员会投票赞成将3种2C-苯乙胺衍生物（25B-NBOMe、25C-NBOMe和25I-NBOMe）列入联合国精神药物公约1971一揽表I中。2C-苯乙胺是具有兴奋和致幻性质的高效合成致幻剂。作为“策划药”，该药迅速出现在市场上。此类策划药容易在网络上及舞会、夜总会和时装店销售。在全球范围内，这些产品与重大健康与安全风险相关。2C-苯乙胺没有合法治疗或工业用途，仅限于科学研究使用。 本公告给相关利益方提供机会，评议加拿大卫生部关于受管制药品及物质法案（CDSA）一揽表III及食品药品法规（FDR）第J部分一揽表修订提案，以便包括2C-苯乙胺及其盐类、衍生物、同分异构体，和衍生物与同分异构体及其盐类。这将包括25B-NBOMe、25C-NBOMe和25I-NBOMe及其盐类。
|
正文:
| 世界贸易组织 |
G/TBT/N/CAN/465
2015-08-05
15-4028
|
| |
| 技术性贸易壁垒 |
原文：英语/法语
|
通 报
以下通报根据TBT协定第10.6条分发
| 1. |
通报成员: 加拿大
如可能，列出涉及的地方政府名称 ( 3.2条和7.2 条)：
|
| 2. |
负责机构:卫生部
|
| 3. |
通报依据条款:2.9.2
|
| 4. |
覆盖的产品： 2C-苯乙胺及其盐类、衍生物、同分异构体，衍生物与同分异构体及其盐类。 ICS: 11.120
HS编码:30 ICS编码:11.120
|
| 5. |
通报标题： 给相关利益方的公告－受管制药品及物质法案（CDSA）一揽表III及食品药品法规（FDR）第J部分一揽表修订提案，以便包括2C-苯乙胺及其盐类、衍生物、同分异构体，和衍生物与同分异构体及其盐类。
语言：英语和法语 页数：2 链接网址：
|
| 6. |
内容简述： 联合国麻醉药品委员会投票赞成将3种2C-苯乙胺衍生物（25B-NBOMe、 25C-NBOMe和25I-NBOMe）列入联合国精神药物公约1971一揽表I中。2C-苯乙胺是具有兴奋和致幻性质的高效合成致幻剂。作为“策划药”，该药迅速出现在市场上。此类策划药容易在网络上及舞会、夜总会和时装店销售。在全球范围内，这些产品与重大健康与安全风险相关。2C-苯乙胺没有合法治疗或工业用途，仅限于科学研究使用。
本公告给相关利益方提供机会，评议加拿大卫生部关于受管制药品及物质法案（CDSA）一揽表III及食品药品法规（FDR）第J部分一揽表修订提案，以便包括2C-苯乙胺及其盐类、衍生物、同分异构体，和衍生物与同分异构体及其盐类。这将包括25B-NBOMe、 25C-NBOMe和25I-NBOMe及其盐类。
|
| 7. |
目标与理由:保护人类健康。
|
| 8. |
相关文件: 2015年8月1日加拿大官方公报第I部分第2158-2159页（英语和法语）
|
| 9. |
拟批准日期:预计2016年春
拟生效日期:法规批准之日
|
| 10. |
意见反馈截止日期： 2015/10/15
|
| 11. |
文本可从以下机构得到:
|
|
正文(英):
NOTIFICATION
The following notification is being circulated in accordance with Article 10.6
|
1.
|
Notifying Member: Canada
If applicable, name of local government involved (Article 3.2 and 7.2):
|
|
2.
|
Agency responsible: Health Canada
Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:
Canada's Notification Authority and Enquiry Point
Foreign Affairs, Trade and Development Canada
Technical Barriers and Regulations Division (TIB)
111 Sussex Drive
Ottawa, ON K1A 0G2
Canada
Tel: (343) 203-4273
Fax: (613) 943-0346
E-mail: enquirypoint@international.gc.ca
|
|
3.
|
Notified under Article 2.9.2 [X], 2.10.1 [ ], 5.6.2 [ ], 5.7.1 [ ], other:
|
|
4.
|
Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable): 2C-phenethylamines and their salts, derivatives, isomers and salts of derivatives and isomers (ICS: 11.120)
|
|
5.
|
Title, number of pages and language(s) of the notified document: Notice to Interested Parties – Proposed Order amending Schedule III to the Controlled Drugs and Substances Act (CDSA) and Regulations Amending the Schedule to Part J of the Food and Drug Regulations (FDR) to include 2C-phenethylamines and their salts, derivatives, isomers and salts of derivatives and isomers (2 pages, available in English and French)
|
|
6.
|
Description of content: The United Nations Commission on Narcotic Drugs voted in favour of scheduling three 2C-phenethylamines derivatives, 25B-NBOMe, 25C-NBOMe, and 25I-NBOMe, under Schedule I to the United Nations Convention on Psychotropic Substances 1971. 2C-phenethylamines are potent synthetic hallucinogens having both stimulant and hallucinogenic properties. Considered as "designer drugs", they are emerging in the market at a rapid pace. These designer drugs are readily available for sale on the internet as "research chemicals" and at raves, nightclubs and head shops. Around the world, these products have been associated with significant health and safety risks. There are no known legitimate therapeutic or industrial uses and only limited scientific and research uses for 2C-phenethylamines.
This notice provides interested stakeholders with the opportunity to comment on Health Canada's intent to pursue amendments to Schedule III to the CDSA and the Schedule to Part J of the FDR to include 2C-phenethylamines and their salts, derivatives, isomers and salts of derivatives and isomers. This would include 25B-NBOMe, 25C-NBOMe and 25I?NBOMe and their salts.
|
|
7.
|
Objective and rationale, including the nature of urgent problems where applicable: Protection of human health
|
|
8.
|
Relevant documents: Canada Gazette, Part I, 1 August 2015, Pages 2158-2159 (Available in English and French)
|
|
9.
|
Proposed date of adoption: Anticipated for spring 2016
Proposed date of entry into force: On the date the regulations are adopted
|
|
10.
|
Final date for comments: 15 October 2015
|
|
11.
|
Texts available from: National enquiry point [X] or address, telephone and fax numbers and email and website addresses, if available, of other body:
The electronic version of the notice can be downloaded at:
http://www.gazette.gc.ca/rp-pr/p1/2015/2015-08-01/pdf/g1-14931.pdf
http://www.gazette.gc.ca/rp-pr/p1/2015/2015-08-01/html/notice-avis-eng.php#nb4
http://www.gazette.gc.ca/rp-pr/p1/2015/2015-08-01/html/notice-avis-fra.php#nb4
|
|
| |
|
